Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 8, 2002, Pages 3721-3727

  Tang, Xiaohui ^a   Yano, Tetsu ^a   Osuga, Yutaka ^b   Matsumi, Hirotaka ^a   Yano, Naomi ^b   Xu, Jiping ^a   Wada, Osamu ^b   Koga, Kaori ^a   Kugu, Koji ^b   Tsutsumi, Osamu ^a   Schally, Andrew V ^b   Taketani, Yuji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CETRORELIX; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; MESSENGER RNA; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; EPITHELIUM CELL; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LABELING INDEX; MITOSIS INHIBITION; NICK END LABELING; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEADY STATE; WESTERN BLOTTING;

FALLOPIA;

EID: 18544374444     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.8.8726     Document Type: Article

References (46)

1. Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis
2. Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium
3. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines
4. Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: Role of apoptosis
5. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone
6. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75
7. The use of luteinizing hormone-releasing hormone agonists and antagonists in gynaecological cancers
8. Luteinizing hormone-releasing hormone agonist triptorelin antagonist signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines
9. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells
10. Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line
11. Antitumor effect of GnRH agonist in epithelial ovarian cancer
12. Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro
13. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix
14. Gonadotropin-releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types
15. Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma
16. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines
17. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice
18. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors
19. Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane
20. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers
21. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein α(I)-mediated activation of phosphotyrosine phosphatase
22. Luteinizing hormone-releasing hormone induces nuclear factor κB-activation and inhibits apoptosis in ovarian cancer cells
23. First results of the GnRH antagonists cetrorelix in patients with ovarian cancer
24. Characterization of newly established human ovarian carcinoma cell line - Special reference of the effects of cis-platinum on cellular proliferation and release of CA125
25. Isolation of the gene and hypothalamic cDNA for the common precursor of gonadotropin-releasing hormone and prolactin release-inhibiting factor in human and rat
26. Cloning and characterization of the human GnRH receptor
27. Autocrine role of gonadotropin-releasing hormone and its receptor in ovarian cancer cell growth
28. Principles of CDK regulation
29. Recent advances on cyclins, CDKs and CDK inhibitors
30. Cancer cell cycles
31. Cyclin A is required at two points in the human cell cycle
32. Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A
33. Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1
34. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts
35. CDK inhibitors: Positive and negative regulators of G1-phase progression
36. p21 is a universal inhibitor of cyclin kinases
37. WAF1, a potential mediator of p53 tumor suppression
38. Induction of WAF1/CIP1 by a p53-independent pathway
39. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage
40. p53 tumor-suppressor gene: Clues to molecular carcinogenesis
41. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53
42. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein
43. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts
44. Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: Possible mechanism for hormonal control of apoptotic cell death
45. Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells
46. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis